Do You Believe in the Growth Potential of STERIS (STE)?

Group 1: Upslope Capital Management Performance - Upslope Capital Management reported a strong performance in Q3 2025, achieving a net return of +8.8%, outperforming the S&P Midcap 400 ETF (+5.5%) and HFRX Equity Hedge Index (+3.8%) [1] Group 2: STERIS plc Overview - STERIS plc, headquartered in Dublin, Ireland, specializes in infection prevention products and services, with a market capitalization of $23.73 billion as of October 22, 2025 [2] - The stock of STERIS plc experienced a one-month return of -1.44% but gained 5.91% over the last 52 weeks, closing at $242.37 per share [2] Group 3: STERIS plc Investment Insights - STERIS plc is recognized as a leader in infection prevention and sterilization, with approximately 75% of sales derived from service and consumables, historically achieving high single-digit organic growth [3] - The company's valuation is considered reasonable at 22x 2026 EPS, and it maintains a strong balance sheet with 1x net leverage, presenting opportunities for capital deployment [3] - Long-term growth drivers for STERIS plc include an aging global population and ongoing innovations in healthcare procedures and technology [3] Group 4: Hedge Fund Interest in STERIS plc - STERIS plc was held by 50 hedge fund portfolios at the end of Q2 2025, an increase from 46 in the previous quarter, indicating growing interest among institutional investors [4]